Abstract:
Anemia is a common in patients with chronic renal failure specially in
patients requiring hemodialysis. An important factor in successful
treatment of anemia by giving erythropoietin stimulating agent combined
with supplementary iron. So, iron status must be monitored regularly to
ensure maintenance of adequate iron supplements without adverse effect
of excess iron.
This study aimed to evaluate body iron status in Sudanese patients with
end stage chronic renal failure treated with regular hemodialysis,
recombinant erythropoietin and iron supplement, and correlate iron
profile with age, gender and duration of hemodialysis.
Eighty patients were included in this study from two dialysis centers in
Khartoum states (Ahmed Gasim and Asbab hospitals) . Data collected
using structured interview questionnaire. Hematological parameters were
measured using automated haematology analyzer (sysmex). Serum iron,
total iron binding capacity (TIBC), and Serum ferritin measured using
Bio system 350 semi automated spectrophotometer, and transferrin
saturation percentage was calculated using the results of serum iron and
total iron binding capacity. Data analyzed using statistical package for
social sciences (SPSS).
Seventy five out of eighty patients (93.7%) were received regular
intravenous iron dextran with EPO, and 5 patients (6.3%) were received
oral iron.
Sixty five patients out of eighty (81.2%) were found to have anemia with
Hb concentration <11 g\dl, the mean was 9.69±1.72. While high S.ferritin
level with more than 800 µg\l were found in 71.2% of patients (57\80), of
them the TSAT was > 50% in 27 patients (33.8%). Increase S.ferritin was
statistically significant with duration of dialysis and with increase
intravenous iron doses, result values were 0.017 and 0.040 respectively.
There were no influence of patients age or gender on iron profile.
In conclusion, patients with HDCKD who were treated with intravenous
iron are prone to iron over load.
